Cara Therapeutics | CARA - Gross Profit On Sales


Cara Therapeutics reported $2.57M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Assertio Holdings USD 22.24M 970K Jun/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Chugai Pharma JPY 258.74B 25.81B Dec/2025
Cipla INR 41.64B 6.31B Dec/2025
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 63.8M 63.56M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
J&J USD 17.24B 642M Mar/2026
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Pacira USD 126.64M 15.61M Mar/2026
Pfizer USD 12.28B 8.74B Dec/2025
RedHill Biopharma USD 584K 0 Jun/2024
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024